EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice

J.L.  Spencer Clinton; Tabitha Hoornweg; J. Tan,; Rongsheng Peng; Willem Schaftenaar; VP Rutten; Xander de Haan; P.D. Ling

doi:10.1016/j.vaccine.2022.07.016

EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice

J.L. Spencer Clinton, Tabitha Hoornweg, J. Tan,, Rongsheng Peng, Willem Schaftenaar, VP Rutten, Xander de Haan, P.D. Ling^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Asian elephants are an endangered species facing many threats, including severe hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the leading cause of death in captive juvenile Asian elephants in North America and Europe, and also affects elephants in their natural range countries. Significant challenges exist for successful treatment of EEHV-HD, which include timely recognition of disease onset and limited availability of highly effective treatment options. To address this problem, our goal is to prevent lethal disease in young elephants by developing a vaccine that elicits robust and durable humoral and cell-mediated immunity against EEHV. EEHV glycoprotein B (gB) is a major target for cellular and humoral immunity in elephants previously exposed to EEHV. Therefore, we generated a vaccine containing recombinant EEHV1A gB together with a liposome formulated TLR-4 and saponin combination adjuvant (SLA-LSQ). CD-1 mice that received one or two vaccinations with the vaccine elicited significant anti-gB antibody and polyfunctional CD4+ and CD8+ T cell responses, while no adverse effects of vaccination were observed. Overall, our findings demonstrate that an adjuvanted gB protein subunit vaccine stimulates robust humoral and cell-mediated immune responses and supports its potential use in elephants.

Original language	English
Pages (from-to)	5131-5140
Number of pages	10
Journal	Vaccine
Volume	40
Issue number	35
Early online date	22 Jul 2022
DOIs	https://doi.org/10.1016/j.vaccine.2022.07.016
Publication status	Published - 19 Aug 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors

Funding

This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (CA125123 and RR024574), and the assistance of Joel M. Sederstrom. Additionally, we would like to express our gratitude to Tony A. Smits for technical assistance in expression of the gB antigen. This work was supported by funding from the International Elephant Foundation (IEF) and Houston Zoo to Paul D. Ling and funds acquired via Named Fund Friends of VetMed to the Utrecht University EEHV research group (TH, VR, and CdH).

Funders	Funder number
National Institutes of Health	RR024574, CA125123
International Elephant Foundation

Keywords

Herpesvirus
Elephant endotheliotropic herpesvirus
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2022.07.016Licence: CC BY

1-s2.0-S0264410X2200891X-mainFinal published version, 1.58 MBLicence: CC BY

Cite this

@article{a4582e0b67b34c79a8282d54b6dad32a,

title = "EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice",

abstract = "Asian elephants are an endangered species facing many threats, including severe hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the leading cause of death in captive juvenile Asian elephants in North America and Europe, and also affects elephants in their natural range countries. Significant challenges exist for successful treatment of EEHV-HD, which include timely recognition of disease onset and limited availability of highly effective treatment options. To address this problem, our goal is to prevent lethal disease in young elephants by developing a vaccine that elicits robust and durable humoral and cell-mediated immunity against EEHV. EEHV glycoprotein B (gB) is a major target for cellular and humoral immunity in elephants previously exposed to EEHV. Therefore, we generated a vaccine containing recombinant EEHV1A gB together with a liposome formulated TLR-4 and saponin combination adjuvant (SLA-LSQ). CD-1 mice that received one or two vaccinations with the vaccine elicited significant anti-gB antibody and polyfunctional CD4+ and CD8+ T cell responses, while no adverse effects of vaccination were observed. Overall, our findings demonstrate that an adjuvanted gB protein subunit vaccine stimulates robust humoral and cell-mediated immune responses and supports its potential use in elephants.",

keywords = "Herpesvirus, Elephant endotheliotropic herpesvirus, Vaccine",

author = "\{Spencer Clinton\}, J.L. and Tabitha Hoornweg and J. Tan, and Rongsheng Peng and Willem Schaftenaar and VP Rutten and \{de Haan\}, Xander and P.D. Ling",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = aug,

day = "19",

doi = "10.1016/j.vaccine.2022.07.016",

language = "English",

volume = "40",

pages = "5131--5140",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "35",

}

TY - JOUR

T1 - EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice

AU - Spencer Clinton, J.L.

AU - Hoornweg, Tabitha

AU - Tan,, J.

AU - Peng, Rongsheng

AU - Schaftenaar, Willem

AU - Rutten, VP

AU - de Haan, Xander

AU - Ling, P.D.

PY - 2022/8/19

Y1 - 2022/8/19

N2 - Asian elephants are an endangered species facing many threats, including severe hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the leading cause of death in captive juvenile Asian elephants in North America and Europe, and also affects elephants in their natural range countries. Significant challenges exist for successful treatment of EEHV-HD, which include timely recognition of disease onset and limited availability of highly effective treatment options. To address this problem, our goal is to prevent lethal disease in young elephants by developing a vaccine that elicits robust and durable humoral and cell-mediated immunity against EEHV. EEHV glycoprotein B (gB) is a major target for cellular and humoral immunity in elephants previously exposed to EEHV. Therefore, we generated a vaccine containing recombinant EEHV1A gB together with a liposome formulated TLR-4 and saponin combination adjuvant (SLA-LSQ). CD-1 mice that received one or two vaccinations with the vaccine elicited significant anti-gB antibody and polyfunctional CD4+ and CD8+ T cell responses, while no adverse effects of vaccination were observed. Overall, our findings demonstrate that an adjuvanted gB protein subunit vaccine stimulates robust humoral and cell-mediated immune responses and supports its potential use in elephants.

AB - Asian elephants are an endangered species facing many threats, including severe hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the leading cause of death in captive juvenile Asian elephants in North America and Europe, and also affects elephants in their natural range countries. Significant challenges exist for successful treatment of EEHV-HD, which include timely recognition of disease onset and limited availability of highly effective treatment options. To address this problem, our goal is to prevent lethal disease in young elephants by developing a vaccine that elicits robust and durable humoral and cell-mediated immunity against EEHV. EEHV glycoprotein B (gB) is a major target for cellular and humoral immunity in elephants previously exposed to EEHV. Therefore, we generated a vaccine containing recombinant EEHV1A gB together with a liposome formulated TLR-4 and saponin combination adjuvant (SLA-LSQ). CD-1 mice that received one or two vaccinations with the vaccine elicited significant anti-gB antibody and polyfunctional CD4+ and CD8+ T cell responses, while no adverse effects of vaccination were observed. Overall, our findings demonstrate that an adjuvanted gB protein subunit vaccine stimulates robust humoral and cell-mediated immune responses and supports its potential use in elephants.

KW - Herpesvirus

KW - Elephant endotheliotropic herpesvirus

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85134765716

U2 - 10.1016/j.vaccine.2022.07.016

DO - 10.1016/j.vaccine.2022.07.016

M3 - Article

SN - 0264-410X

VL - 40

SP - 5131

EP - 5140

JO - Vaccine

JF - Vaccine

IS - 35

ER -

EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this